AD-PS1 hiPSC

General#

Cell Line

hPSCreg Name IRMBi001-A
Alternative name(s)
AD-PS1 hiPSC
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 8th August 2018
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Institute for Regenerative Medecine and Biotherapy (IRMB)
Owner Institute for Regenerative Medecine and Biotherapy (IRMB)
Distributors
Derivation country France

External Databases

BioSamples SAMEA104618388
Cellosaurus CVCL_VD86

General Information

Publications
Is the cell line available in principle?
No

Donor Information#

General Donor Information

Sex male

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Alzheimer's disease
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Disease, Alzheimer
  • Dementia in Alzheimer's disease, unspecified (disorder)
  • Presenile Alzheimer Dementia
  • ALZHEIMERS DIS
  • Alzheimers
  • DAT - Dementia Alzheimer's type
  • Dementia in Alzheimer's disease
  • Alzheimer's disease, NOS
  • Alzheimer Dementia, Presenile
  • Dementia, Alzheimer Type
  • Alzheimer Dementia
  • Alzheimer's Dementia
  • Alzheimer's
  • Dementia, Presenile
  • [X]Dementia in Alzheimer's disease (disorder)
  • ALZHEIMER DIS
  • AD
  • [X]Dementia in Alzheimer's disease
  • AD - Alzheimer's disease
  • Disease, Alzheimer's
  • Alzheimer Disease
  • Dementia, Presenile Alzheimer
  • Alzheimer Type Dementia
  • Dementia in Alzheimer's disease (disorder)
  • Alzheimer's disease (disorder)
  • Alzheimers Dementia
  • Dementia of the Alzheimer's type
  • sporadic Alzheimer's disease
  • Alzheimers disease
show more synonyms
Is the medical history available upon request? Yes
Is clinical information available? Yes

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unkown

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA104618388

Ethics#

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Provide contact information of the holder of the original Donor Information Sheet:
Do you (Depositor/Provider) hold a copy of the SIGNED Donor Consent Form? No
If you do not hold the SIGNED Donor Consent Form, do you know who does? Yes
Contact information / weblink Dr David Wallon, Pr Alexis Brice, INSERM Rouen
If you do not hold the SIGNED Donor Consent Form, have you obtained a copy of the unsigned Donor Consent Form from the holder? Yes
Alternatives to consent are available? No
Alternatives to consent
Alternative consent approval number
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? No
Details on restriction to research project
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? Yes
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? No
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? No
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
Policy for access to genetic information Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? Yes
Please describe how access is provided: Controlled access anonymized
Does consent permit access to any other source of information about the clinical treatment or health of the donor? Yes
Contact data, institution, or website: INSERM, CHU Rouen
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? CPP Paris Pitié Salpêtrière
Approval number 2008/067/HP 110-05
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Direction Générale de la recherche et de l'innovation
Approval number IE-2013-675(4)/DC-2015-2363
Do you have obligations to third parties in regard to the use of the cell line? Yes
Please describe: INSERM has the intellectual property
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Further constraints on use
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? ThermoFisher
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No
Constraints for use or distribution

hIPSC Derivation#

General

Source cell type
fibroblast
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.
Source cell origin
zone of skin
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
  • portion of skin
  • skin zone
  • region of skin
  • skin region
  • skin
show more synonyms
Passage number reprogrammed 3

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Other

Selection criteria for clones Morphology and in vivo detection of SSEA4 Thermofisher Kit
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Gelatin
Feeder cells MEF
Passage method Mechanically
O2 Concentration 5 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: KODMEM/F12
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
NEAA 1 %
b-mercaptoethanol 0,1 mM
L-Glutamine 1 mM
Penicilline 100 U/ml
Streptomycine 100 µg/ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
NANOG
Yes
SOX2
Yes
SSEA-4
Yes
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
AFP
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
a-SMA
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
BIII-tubulin
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46XY
Karyotyping method: G-Banding

Other Genotyping (Cell Line)